

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee, 2013
(including the 18th WHO Model List of Essential Medicines
and the 4th WHO Model List of Essential Medicines for Children)



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries).

For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee, 2013
(including the 18th WHO Model List of Essential Medicines
and the 4th WHO Model List of Essential Medicines for Children)

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO model list of essential medicines and the 4th WHO model list of essential medicines for children).

(WHO technical report series ; no. 985)

1. Drugs, Essential – therapeutic use. 2. Drugs, Essential – standards. 3. Drug information services. 4. Drug utilization. 5. Child. I. World Health Organization. II. Series.

ISBN 978 92 4 120985 4
ISSN 0512-3054

(NLM classification: QV 55)

© World Health Organization 2014

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy

Contents

Executive summary	vii
List of participants	xi
Declarations of interests	xiii
1. Introduction	1
2. Open session	2
3. General items	4
3.1 Defining public health relevance	4
3.2 Medicines information as a global public good	5
3.3 Other	7
4. Applications only for paediatric medicines	8
Section 1: Anaesthetics	8
Anaesthetics (review) – Children	8
Section 2: Non-steroidal anti-inflammatory medicines (NSAIDs) and medicines used to treat gout and disease-modifying agents in rheumatoid disorders (DMARDs)	9
2.2: Opioid analgesics	9
Hydromorphone (addition) – Children	9
Oxycodone (addition) – Children	9
Morphine (new formulation) – Children	10
Section 6: Anti-infective medicines	11
6.2: Antibacterials	11
6.2.4: Antituberculosis medicines	11
Second-line antituberculosis medicines (review) – Children	11
Streptomycin injections (to be moved to the complementary list) – Children	15
6.4: Antiviral medicines	15
6.4.2: Antiretrovirals	15
Abacavir (new formulation); Abacavir + lamivudine (addition);	
Efavirenz (new formulation); Lamivudine + nevirapine + zidovudine (new formulation); Lamivudine + stavudine (new formulation);	
Lamivudine + zidovudine (new formulation); Nevirapine (new formulation)	15
6.5: Antiprotozoal medicines	16
6.5.5: Antitrypanosomal medicines	16
6.5.5.1: African trypanosomiasis	16
Nifurtimox tablets (addition) – Children	16
6.5.5.2: American trypanosomiasis	17
Benznidazole tablets (new formulation) – Children	17
Section 8: Antineoplastics	18
8.4: Medicines used in palliative care	18
Palliative care (new section) – Children	18
Section 11: Blood products and plasma substitutes	19
11.1: Plasma substitutes	19
Colloids (review) – Children	19

Section 12: Cardiovascular medicines	21
12.2: Antiarrhythmic medicines	21
Antiarrhythmics (review) – Children	21
12.6: Lipid-lowering agents	22
Statins (review) – Children	22
Section 15: Disinfectants and antiseptics	23
15.1: Antiseptics	23
Chlorhexidine (new formulation) – Children	23
Section 24: Medicines for mental and behavioural disorders	24
24.1: Medicines used in psychotic disorders	24
Chlorpromazine and haloperidol (deletion) – Children only	24
24.2: Medicines used in mood disorders	25
24.2.1: Medicines used in depressive disorders	25
Fluoxetine (change to age restriction/deletion from EMLc) – Adults and Children	25
Section 28: Ear, nose and throat medicines	25
Montelukast (addition) – Children	25
Section 29: Specific medicines for neonatal care	26
Dexamethasone (new indication) – Children	26
5. Applications for the 18th Model List and the 4th EMLc	29
Section 2: NSAIDs and DMARDs	29
2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)	29
Naproxen (addition) – Adults	29
2.3: Medicines used to treat gout	30
Colchicine (reinstatement) – Adults	30
Section 3: Antiallergics and medicines used in anaphylaxis	32
Histamine-1 receptor antagonists (review) – Adults and Children	32
Section 4: Antidotes and other substances used in poisonings	33
Fomepizole (addition) – Adults and Children	33
Section 6: Anti-infective medicines	35
6.2: Antibacterials	35
6.2.2: Other antibacterials	35
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (addition) – Adults and Children	35
6.2.4: Antituberculosis medicines	36
6.3: Antifungal medicines	37
Amphotericin B (to be moved to the core list);	
Flucytosine (to be moved to the core list) – Adults and Children	37
6.4: Antiviral medicines	39
6.4.2: Antiretrovirals	39
Abacavir + Lamivudine (addition); Atazanavir + Ritonavir (addition);	
Tenofovir disoproxil fumarate + Lamivudine (addition); Tenofovir	
disoproxil fumarate + Lamivudine + Efavirenz (addition) – Adults	39
Antiretrovirals (formulations to be considered for possible deletion) – Adults and Children	39
6.4.3: Other antivirals	39
Oseltamivir (deletion) – Adults and Children	39
Pegylated interferon (addition) – Adults	41

6.5: Antiprotozoal medicines	43
6.5.3: Antimalarial medicines	43
6.5.3.1: For curative treatment	43
Artesunate + mefloquine (addition) – Adults and Children	43
6.5.5: Antitrypanosomal medicines	44
6.5.5.1: African trypanosomiasis	44
Nifurtimox + eflornithine (review) – Adults and Children	44
Section 8: Antineoplastics, immunosuppressives and medicines used in palliative care	44
8.2: Cytotoxic and adjuvant medicines	44
Imatinib (addition) – Adults	45
Imatinib (addition) – Adults and Children	45
Trastuzumab (addition) – Adults	46
8.4: Medicines used in palliative care	48
Section 9: Antiparkinsonism medicines	52
Antiparkinsonism medicines (review) – Adults	52
Section 10: Medicines affecting the blood	53
10.1: Antianaemia medicines	53
Ferrous salt + folic acid (new formulation) – Adults	53
Section 11: Blood products and plasma substitutes	55
11.2: Plasma fractions for specific use	55
Human normal immunoglobulin (additional dosage) – Adults and Children	55
Whole blood and red blood cells (addition) – Adults and Children	55
Section 12: Cardiovascular medicines	58
Fixed-dose combination for secondary prevention of cardiovascular disease (addition) – Adults	58
12.4: Medicines used in heart failure	60
Spironolactone (new indication) – Adults	60
Section 13: Dermatological medicines (topical)	62
13.4: Medicines affecting skin differentiation and proliferation	62
Benzoyl peroxide (review) – Adults and Children	62
Coal tar (review) – Adults	62
Dithranol (deletion) – Adults	63
Section 17: Gastrointestinal medicines	64
17.1: Antiulcer medicines	64
Antiulcer medicines (review) – Adults	64
Section 18: Hormones, other endocrine medicines and contraceptives	65
18.5: Insulins and other medicines used for diabetes	65
Glibenclamide (review) – Adults	65
Oral hypoglycaemics (review) – Adults	67
Section 21: Ophthalmological preparations	68
Azithromycin (addition) – Adults and Children	68
Bevacizumab (addition) – Adults	70
Ketorolac (addition) – Adults	72
Ketotifen (addition) – Adults and Children	73
Latanoprost (addition) – Adults	73
Ofloxacin (addition) – Adults and Children	74

Section 22: Oxytocics and antioxytocics	75
22.1: Oxytocics	75
Misoprostol (deletion) for prevention of postpartum haemorrhage – Adults	75
Misoprostol (new indication) – Adults	76
Section 24: Medicines for mental and behavioural disorders	77
24.1: Medicines used in psychotic disorders	77
Clozapine (addition as complementary medicine) – Adults	78
24.2: Medicines used in mood disorders	79
24.2.1: Medicines used in depressive disorders	79
Fluoxetine (change to age restriction/deletion from EMLc) –	
Adults and Children	79
Risperidone (addition) – Adults	79
Section 27: Vitamins and minerals	81
Calcium (addition) – Adults	81
Section 28: Ear, nose and throat medicines	82
Ear, nose and throat (review) – Adults and Children	82
6. Summary of recommendations	83
18th WHO Model List of Essential Medicines	83
Additions to Model List	83
Deletions from Model List	84
Changes to sections	84
Deferred applications	85
Rejected applications	85
4th Essential Medicines List for Children	86
Additions to EMLc	86
Deletions from EMLc	87
Changes to sections	87
Amended dosage strength and form	87
Rejected applications	88
Recommendations for reviews	88
References	89
Annex 1	
18th WHO Model List of Essential Medicines (April 2013)	107

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>